Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.
Rawan G FaramandSae Bom LeeMichael D JainBiwei CaoXuefeng WangMarion SubkleweMarion SubkleweJohannes F FahrmannNeeraj Y SainiSamir M HanashYun Pyo KangDarwin ChangPaulo C RodriguezErin A DeanTaiga NishihoriBijal D ShahAleksander LazaryanJulio C ChavezFarhad KhimaniJavier A Pinilla-IbarzMarian DamKayla M ReidSalvatore A CoralloMeghan MengesMelanie Hidalgo VargasJessica K MandulaBrian A HollidayChristina A BachmeierKelly A SpethQinghua SongMike MattieFrederick L LockeMarco L DavilaPublished in: Blood cancer discovery (2024)
CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes. This article is featured in Selected Articles from This Issue, p. 80.